Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most statements are about stopping bupropion suddenly and specific withdrawal-like symptoms, which are not supported by the provided WELLBUTRIN XL label excerpts (boxed warning/warnings about suicidality and monitoring only). Several urgent-action symptoms also exceed the provided label content.
Category Scores
Accurate Statements
Urgent care or contact a clinician immediately if suicidal thoughts occur.
Boxed Warning and Warnings state patients should be monitored for suicidality and report emergence of suicidality/unusual behavior immediately to healthcare providers (close observation and communication with the prescriber).
Urgent care or contact a clinician immediately if depression severely worsens.
Warnings state patients may experience worsening of depression and should be monitored closely for clinical worsening, and therapeutic regimen should be considered/changing in persistently worse depression; families/caregivers should report such symptoms immediately.
Unsupported Statements
Stopping Wellbutrin (bupropion) suddenly can cause withdrawal-like symptoms.
The provided label excerpts do not mention withdrawal-like symptoms from abrupt discontinuation of WELLBUTRIN XL.
The brain adapts to bupropion over time.
Not supported by the provided label excerpts.
Stopping Wellbutrin suddenly can cause flu-like feelings.
Not supported by the provided label excerpts.
Stopping Wellbutrin suddenly can cause mood changes.
Not supported by the provided label excerpts as a discontinuation effect.
Stopping Wellbutrin suddenly can cause mood changes.
Not supported by the provided label excerpts as a discontinuation effect.
Stopping Wellbutrin suddenly can cause irritability.
The Warnings list irritability as a symptom reported during antidepressant treatment, not as a sudden-discontinuation effect; provided excerpts do not support this discontinuation-specific claim.
Stopping Wellbutrin suddenly can cause anxiety.
Anxiety is listed among symptoms reported during antidepressant treatment as potential precursors to suicidality; the provided excerpts do not support that abrupt discontinuation causes anxiety.
Stopping Wellbutrin suddenly can cause dizziness.
Not supported by the provided label excerpts.
Stopping Wellbutrin suddenly can cause headache.
Not supported by the provided label excerpts.
Stopping Wellbutrin suddenly can cause trouble sleeping.
Insomnia is listed as a symptom reported during antidepressant treatment, not as an abrupt-discontinuation effect in the provided excerpts.
Stopping Wellbutrin suddenly can cause original depression symptoms to return or worsen.
The Warnings discuss worsening of depression during treatment and need to consider regimen changes; provided excerpts do not specifically support return of original symptoms due to sudden stopping.
Stopping Wellbutrin (bupropion) cold turkey is usually not recommended for people who have been taking it regularly.
Not supported by the provided label excerpts.
Stopping Wellbutrin cold turkey is especially not recommended for people taking moderate to higher doses or taking it for a long time.
Not supported by the provided label excerpts.
A safer approach to stopping Wellbutrin is usually a gradual taper guided by a clinician.
Not supported by the provided label excerpts.
The right discontinuation plan depends on dose, how long it has been taken, and the reason for stopping.
Not supported by the provided label excerpts.
Doctors often reduce the dose step-by-step over weeks rather than stopping abruptly.
Not supported by the provided label excerpts.
The exact taper schedule varies by dose and individual response.
Not supported by the provided label excerpts.
For serious side effects such as seizure, severe allergic reaction, or dangerous-feeling agitation, urgent medical advice should be sought rather than tapering on your own.
The provided excerpts include a seizure contraindication (seizure disorder) and mention concern about agitation as a symptom reported during antidepressant treatment; they do not support the specific discontinuation/tapering instruction or the seizure/allergic reaction/tapering-on-your-own guidance.
If experiencing more typical side effects such as insomnia, jitteriness, or nausea, the prescriber may adjust the dose or timing and may still use a taper if stopping is needed.
Not supported by the provided label excerpts.
Urgent care or contact a clinician immediately if hallucinations or confusion occur.
The provided excerpts do not mention hallucinations/confusion as triggers for urgent action.
Urgent care or contact a clinician immediately if mania symptoms occur.
Mania is listed among symptoms reported during antidepressant treatment; however, the provided excerpts do not specify an 'urgent care/contact immediately' instruction specifically for mania.
Urgent care or contact a clinician immediately if seizure activity occurs.
The provided excerpts include contraindication in patients with seizure disorder but do not provide urgent discontinuation-related seizure action guidance.
Contradictions
Important Omissions
The provided label excerpts emphasize monitoring for clinical worsening, suicidality, and unusual changes in behavior during antidepressant therapy and especially during initial months or dose changes; the AI response focuses largely on abrupt discontinuation symptom lists without aligning to the label’s monitoring framework.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Many statements are discontinuation/tapering and symptom-related but are not supported by the provided label excerpts. While two statements about suicidality/worsening depression align with boxed warning/monitoring language, most other advice-like instructions are unsupported by the supplied label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Discontinuation/withdrawal-like symptom and tapering guidance is largely unsupported by the provided WELLBUTRIN XL label excerpts; urgent-action triggers exceed what is shown in the label excerpts.
Suggested Improvement
Limit claims to what the provided label supports: monitoring for clinical worsening, suicidality, and unusual changes in behavior (including symptoms listed as possible precursors) and caregiver/patient reporting guidance; avoid asserting abrupt-discontinuation/withdrawal effects or taper schedules unless supported by the relevant label sections not provided here.